Search - tctmd.com

Displaying 601 - 620 of 752

Sort: Relevancy | Date

News Daily News

El Apixaban Superior a la Warfarin con independencia del Tipo y Duración de la FA

May 13, 2013

News Daily News

Apixaban Superior to Warfarin Regardless of A-fib Type, Duration

May 13, 2013

News Industry News

New Four-Year Data From Boston Scientific Demonstrated WATCHMAN® Device Was Superior To Warfarin For Mortality And Primary Efficacy In Patients With Atrial Fibrillation In Long Term Follow-Up Of The P

May 09, 2013

Presentation

Outcomes of Apixaban vs. Warfarin by Type and Duration of A-Fib; Results from the ARISTOTLE Trial

Presenter: Sana M. Al-Khatib

May 06, 2013

News Daily News

La ESC Ofrece Recomendaciones para el Uso de Nuevos Anticoagulantes Orales

Yael L. Maxwell

May 03, 2013

News Daily News

ESC Offers Recommendations on Use of New Oral Anticoagulants

Yael L. Maxwell

May 03, 2013

News Daily News

ASAP Published: Watchman a Safe Option for A-fib Patients Ineligible for Warfarin

Yael L. Maxwell

April 12, 2013

News Daily News

ASAP Publicado: Watchman es una Opción Segura para Pacientes con FA No Aptos para tomar Warfarina

Yael L. Maxwell

April 12, 2013

Presentation

Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation

Presenter: A.R. Harrington

April 05, 2013

News Daily News

Registro Danés: El Dabigatran es Seguro y Eficaz en el Mundo Real

Caitlin E. Cox

April 05, 2013

News Daily News

Danish Registry: Dabigatran Safe, Effective in Real-World Use

Caitlin E. Cox

April 05, 2013

Presentation

Efficacy and Safety of Dabigatran Etexilate vs. Warfarin in ‘Real-World’ Patients with A-Fib

Presenter: T.B. Larsen

March 29, 2013

Presentation

Betrixaban vs. Warfarin in A-fib Patients: Results of a Phase 2, Randomized, Dose-Ranging Study

Presenter: Stuart J. Connolly

March 28, 2013

News Daily News

Yet Another Novel Anticoagulant Shows Promise for Preventing Stroke in A-fib

March 28, 2013

News Daily News

‘Nuisance’ Bleeding After AMI Common, Affects QoL

Yael L. Maxwell

March 28, 2013

News Daily News

Las Hemorragias ‘Molestas’ tras un IAM son Frecuenten e Influyen en la Calidad de Vida

Yael L. Maxwell

March 28, 2013

News Daily News

NEJM Publishes Two More Trials Weakening the Case for PFO Closure

Caitlin E. Cox

March 25, 2013

News Daily News

El NEJM Publica 2 Ensayos Más que Debilitan el Caso del Cierre del FOP

Caitlin E. Cox

March 25, 2013

News Conference News ACC 2013

ACC/i2 2013: Controversy, Late Breaking Trial News Dominate Busy Meeting

L.A. McKeown

March 14, 2013

Presentation ACC 2013

Randomized Trial of LAA Closure vs Warfarin for Stroke/ Thromboembolic Prevention in Patients with Non-valvular Atrial Fibrillation (PREVAIL)

Presenter: David R. Holmes, Jr.

March 08, 2013

Advertisement

El Apixaban Superior a la Warfarin con independencia del Tipo y Duración de la FA

Apixaban Superior to Warfarin Regardless of A-fib Type, Duration

New Four-Year Data From Boston Scientific Demonstrated WATCHMAN® Device Was Superior To Warfarin For Mortality And Primary Efficacy In Patients With Atrial Fibrillation In Long Term Follow-Up Of The P

Outcomes of Apixaban vs. Warfarin by Type and Duration of A-Fib; Results from the ARISTOTLE Trial

La ESC Ofrece Recomendaciones para el Uso de Nuevos Anticoagulantes Orales

ESC Offers Recommendations on Use of New Oral Anticoagulants

ASAP Published: Watchman a Safe Option for A-fib Patients Ineligible for Warfarin

ASAP Publicado: Watchman es una Opción Segura para Pacientes con FA No Aptos para tomar Warfarina

Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation

Registro Danés: El Dabigatran es Seguro y Eficaz en el Mundo Real

Danish Registry: Dabigatran Safe, Effective in Real-World Use

Efficacy and Safety of Dabigatran Etexilate vs. Warfarin in ‘Real-World’ Patients with A-Fib

Betrixaban vs. Warfarin in A-fib Patients: Results of a Phase 2, Randomized, Dose-Ranging Study

Yet Another Novel Anticoagulant Shows Promise for Preventing Stroke in A-fib

‘Nuisance’ Bleeding After AMI Common, Affects QoL

Las Hemorragias ‘Molestas’ tras un IAM son Frecuenten e Influyen en la Calidad de Vida

NEJM Publishes Two More Trials Weakening the Case for PFO Closure

El NEJM Publica 2 Ensayos Más que Debilitan el Caso del Cierre del FOP

ACC/i2 2013: Controversy, Late Breaking Trial News Dominate Busy Meeting

Randomized Trial of LAA Closure vs Warfarin for Stroke/ Thromboembolic Prevention in Patients with Non-valvular Atrial Fibrillation (PREVAIL)

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content